Enzo Biochem(ENZ) - 2021 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q3 2021 was $32.8 million, an increase of 94% year-over-year from $16.9 million [17][20] - Gross margins improved to 49%, up from 26% in the year-ago period, representing an increase of 2,300 basis points [20][21] - GAAP net income was $2.0 million or $0.04 per share, compared to a loss of $9.9 million or negative $0.21 per share in Q3 2020 [23] - Adjusted EBITDA was $2.7 million, a significant improvement from an adjusted loss of $7 million in the same quarter last year [23] Business Line Data and Key Metrics Changes - Clinical services revenue increased nearly 140% to $25 million from $10.5 million in Q3 2020, driven by volume growth in total accessions [21] - Clinical services gross margin increased to 49.1% from 12.9% in Q3 2020, an improvement of over 3,600 basis points [21] - Enzo Life Sciences product gross margin was 48.4%, up from 47.9% year-over-year [22] Market Data and Key Metrics Changes - Total accessions reached over 340,000 in the most recent quarter, an annualized rate of 1.36 million, compared to pre-COVID levels of approximately 800,000 [21] - The company anticipates a gradual return to regular doctor visits and expects academic institutions to reopen fully by the end of the year [14] Company Strategy and Development Direction - The company is transforming into an integrated end-to-end diagnostic products and solutions company, focusing on high-value opportunities and enhancing operational efficiencies [18][27] - Enzo is leveraging its higher-margin testing model demonstrated during COVID-19 to other markets, including women's health and sexually transmitted diseases [15] - The company is actively engaged in discussions for partnerships and potential acquisitions to complement existing activities [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the post-COVID environment, having successfully adapted during the pandemic [13] - The company is implementing operational protocols and a modified sales strategy to address the realities of a post-COVID-19 environment [14] - Management remains optimistic about achieving full-year profitability for the fiscal year ending in July [19] Other Important Information - The company received FDA EUA clearance for its AMPICOLLECT Sample Collection kit for COVID-19 testing [10] - Enzo's GoTestMeNow online platform is expanding testing access directly to consumers [19] - The company has a strong balance sheet with cash and equivalents of $45.8 million as of April 30, 2021 [24] Q&A Session Summary Question: Evolution of academic institution channels post-pandemic - Management confirmed a focus on long-term relationships with academic institutions for testing beyond COVID, including STDs and women's health [30][31] Question: Pathway for diagnostics approval - The company plans to proceed through the FDA pathway for key platform technologies, with LDT approval on many tests [32] Question: Improvement in staffing market - Management noted that the staffing market is improving, with ongoing efforts to fill openings [33][34] Question: Update on new CEO search - Management is exploring opportunities for succession planning and will report when there is news [36][38] Question: Comparison with Cepheid's testing platforms - Management acknowledged similarities but emphasized their focus on cost-efficient technologies that improve margins for clinical labs [37] Question: Involvement of external consultants in strategic review - Management confirmed that Cain Brothers was retained to assist in the strategic review process [39]